TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24091759

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis with additional balloon dilatation
Number of subjects: 386

Group type: COMPARATOR
Intervention: Catheter-directed thrombolysis alone (control group)
Number of subjects: 386
Study: 22327497

Group type: EXPERIMENTAL
Intervention: dTpa-IPV
Number of subjects: 305

Group type: COMPARATOR
Intervention: DTPa-IPV
Number of subjects: 305
Study: 20873894

Group type: EXPERIMENTAL
Intervention: TMC (telephone continuing care with counseling)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: TM (telephone continuing care with monitoring and feedback)
Number of subjects: 252

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 252
Study: 17584319

Group type: EXPERIMENTAL
Intervention: Local PUVA paint
Number of subjects: 25

Group type: COMPARATOR
Intervention: Local narrowband UVB (NB-UVB) phototherapy
Number of subjects: 25
Study: 15983278

Group type: EXPERIMENTAL
Intervention: Housing contingent on drug abstinence (ACH)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Housing not contingent on abstinence (NACH)
Number of subjects: 196

Group type: COMPARATOR
Intervention: No housing (NH)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: All groups (ACH, NACH, NH)
Number of subjects: 196
Study: 12428312

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg p.o.)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Midazolam (0.05 mg.kg‐1 i.m.)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Zopiclone (2 h before operation)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Midazolam (1 h before operation)
Number of subjects: 117
Study: 9467047

Group type: EXPERIMENTAL
Intervention: Granisetron (10 micrograms/kg) administered as a 30-second intravenous bolus infusion
Number of subjects: 623

Group type: COMPARATOR
Intervention: Ondansetron (32 mg) administered as a 15-minute intravenous infusion
Number of subjects: 623
Study: 8582214

Group type: EXPERIMENTAL
Intervention: Local arterial infusion of 5-FU
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (68 patients)
Number of subjects: 19
Study: 2784824

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicardipine (10 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 322817

Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin (250 mg six-hourly for four days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 34
Study: 31738574

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) during surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (SSC after surgery)
Number of subjects: 40
Study: 29061194

Group type: EXPERIMENTAL
Intervention: Health Scout Intervention (community health workers using motivational interviewing and mobile health tools)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Health Scout Intervention
Number of subjects: 2600
Study: 27136906

Group type: EXPERIMENTAL
Intervention: Losmapimod 2.5 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Losmapimod 20 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg (twice daily for 14 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GSK198602
Number of subjects: 41

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 41
Study: 23665155

Group type: EXPERIMENTAL
Intervention: Pre-training evaluation and feedback (EF group)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 330
Study: 22610801

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (1000 micrograms)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 units)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular oxytocin
Number of subjects: 200
Study: 19702597

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg/day (n=9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day (n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy control subjects (n=9)
Number of subjects: 18
Study: 17352093

Group type: EXPERIMENTAL
Intervention: Contacts of smear-positive TB patients
Number of subjects: 246845

Group type: EXPERIMENTAL
Intervention: Contacts of smear-negative TB patients
Number of subjects: 246845

Group type: COMPARATOR
Intervention: Non-contacts (no TB case at home)
Number of subjects: 246845

Group type: EXPERIMENTAL
Intervention: Household contacts with a TB case
Number of subjects: 246845
Study: 16153354

Group type: EXPERIMENTAL
Intervention: CMHN problem-solving treatment
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: generic CMHN treatment
Number of subjects: 247

Group type: COMPARATOR
Intervention: usual GP care
Number of subjects: 247
Study: 11964744

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids
Number of subjects: 0
Study: 9456242

Group type: EXPERIMENTAL
Intervention: GnRHA-based regimen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Expert outlining method
Number of subjects: 19

Group type: COMPARATOR
Intervention: Computer-based threshold method
Number of subjects: 19
Study: 8593925

Group type: EXPERIMENTAL
Intervention: Glibenclamide (2.5 mg X 3/d)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Treatment (TCT)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Glibenclamide + TCT
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 216
Study: 2714050

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Antipyrine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Theophylline and Antipyrine
Number of subjects: 110
Study: 1100179

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment after craniospinal irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who relapsed
Number of subjects: 0
Study: 31600269

Group type: EXPERIMENTAL
Intervention: Maintenance care (prescheduled care)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Symptom-guided care (control intervention)
Number of subjects: 252
Study: 28446548

Group type: EXPERIMENTAL
Intervention: CABG with surgical ventricular reconstruction (SVR)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: CABG without surgical ventricular reconstruction (SVR)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CABG with or without SVR
Number of subjects: 1000
Study: 25924029

Group type: EXPERIMENTAL
Intervention: Robotically assisted minimally invasive bypass surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional bypass surgery
Number of subjects: 70
Study: 24091311

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine (Cervarix®; GlaxoSmithKline Vaccines)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Al[OH]3)
Number of subjects: 120
Study: 21623467

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) at 10% of basal caloric intake
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) at 30% of basal caloric intake
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) at 10% or 30% of basal caloric intake
Number of subjects: 46
Study: 19329361

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2143
Study: 15188794

Group type: EXPERIMENTAL
Intervention: Maintenance oral nifedipine therapy (n=37) administered 20 mg every six hours
Number of subjects: 73

Group type: COMPARATOR
Intervention: No treatment (controls, n=36)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Maintenance oral nifedipine therapy (n=37)
Number of subjects: 73
Study: 10928373

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 170

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Ceftibuten (Salmonella diarrhea)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Norfloxacin (Salmonella diarrhea)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Ceftibuten (Shigella diarrhea)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Norfloxacin (Shigella diarrhea)
Number of subjects: 170
Study: 7747847

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 40
Study: 2293074

Group type: EXPERIMENTAL
Intervention: methoxybutropate
Number of subjects: 30

Group type: COMPARATOR
Intervention: bromeline
Number of subjects: 30
Study: 6166363

Group type: EXPERIMENTAL
Intervention: bleomycin
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Baker's antifol
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 5-fluorodeoxyuridine plus arabinosyl cytosine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: tilorone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: CCNU
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: streptozotocin
Number of subjects: 202
Study: 30791963

Group type: EXPERIMENTAL
Intervention: MBT-DH
Number of subjects: 114

Group type: COMPARATOR
Intervention: MBT-IOP
Number of subjects: 114
Study: 30795889

Group type: EXPERIMENTAL
Intervention: LDR brachytherapy (I-125 seeds, preplanned)
Number of subjects: 60

Group type: COMPARATOR
Intervention: HDR brachytherapy (27 Gy/2 fractions, intraoperative planning)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LDR brachytherapy (peripheral DILs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LDR brachytherapy (central or anterior DILs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: HDR brachytherapy (peripheral DILs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: HDR brachytherapy (central or anterior DILs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of DIL D90 between modalities
Number of subjects: 60
Study: 27939836

Group type: EXPERIMENTAL
Intervention: Triptorelin 22.5 mg given as 24-week depot injections
Number of subjects: 58

Group type: COMPARATOR
Intervention: Subcapsular orchiectomy
Number of subjects: 58
Study: 25883316

Group type: EXPERIMENTAL
Intervention: Subsidies to the majority of the landless poor
Number of subjects: 380

Group type: COMPARATOR
Intervention: Community motivation alone
Number of subjects: 380

Group type: COMPARATOR
Intervention: Supply-side market access intervention
Number of subjects: 380
Study: 24335969

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 158
Study: 22539173

Group type: EXPERIMENTAL
Intervention: Talking Diabetes programme
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 693
Study: 19375088

Group type: EXPERIMENTAL
Intervention: Short loop tail stent
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Long loop tail stent
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Percuflex Plus stent
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Polaris stent
Number of subjects: 236

Group type: COMPARATOR
Intervention: All stents
Number of subjects: 236
Study: 17560293

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) in subjects with high ADMA
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Simvastatin plus L-arginine (3 g/day) in subjects with high ADMA
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) in subjects with low ADMA
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Simvastatin plus L-arginine (3 g/day) in subjects with low ADMA
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: L-arginine (3 g/day) alone in both groups
Number of subjects: 98

Group type: COMPARATOR
Intervention: Endothelium-independent vasodilation
Number of subjects: 98
Study: 15457277

Group type: EXPERIMENTAL
Intervention: Aspirin (125-250 mg) and unfractionated heparin (5,000 units bolus followed by infusion titrated to maintain activated partial thromboplastin time of 50-75 s); Q-wave MI patients also received thrombolytic therapy (1.5 million units of streptokinase)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Aspirin and unfractionated heparin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (15 patients with stable angina)
Number of subjects: 92
Study: 11354590

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423
Study: 9879697

Group type: EXPERIMENTAL
Intervention: MRI evidence of inflammatory lesions in the conus/epiconus region of the spinal cord
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MRI axial images of the conus-epiconus region
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clinical and electrophysiological evaluation
Number of subjects: 12
Study: 8021760

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 63
Study: 31935529

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT), maximum 26 sessions, up to six months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 63
Study: 30121618

Group type: EXPERIMENTAL
Intervention: One-session treatment (OST)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Multisession cognitive-behavioural therapy (CBT)
Number of subjects: 286
Study: 27544612

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 25917214

Group type: EXPERIMENTAL
Intervention: Lattice System Physician's Global Assessment (LS-PGA)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Psoriasis Area and Severity Index (PASI)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Static Physician's Global Assessment (sPGA)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) related to physicians' assessments of body surface area involved with psoriasis (iBSA)
Number of subjects: 445
Study: 24044803

Group type: EXPERIMENTAL
Intervention: Prone tangential field (TF) intensity modulated radiotherapy (IMRT)
Number of subjects: 100
Study: 20868373

Group type: EXPERIMENTAL
Intervention: Incredible Years preventive program plus a shortened six-week version of the SPOKES literacy program
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual community services
Number of subjects: 174
Study: 19887866

Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (64% of patients, median starting dose 1,070 mg/m² b.i.d.)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Capecitabine combination chemotherapy (36% of patients, median starting dose 987 mg/m² b.i.d.)
Number of subjects: 846
Study: 17396057

Group type: EXPERIMENTAL
Intervention: Smoking cessation (48 participants)
Number of subjects: 138
Study: 14766712

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at a starting rate of 6-9 microg kg(‐1) h(‐1) for up to 72 h, with additional propofol (0.5 mg kg(‐1) h(‐1) if required)
Number of subjects: 40
Study: 11688664

Group type: EXPERIMENTAL
Intervention: Bifocal contact lenses
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 21

Group type: COMPARATOR
Intervention: Monofocal contact lenses (controls)
Number of subjects: 21
Study: 9387174

Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 8183520

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic flurbiprofen (added to topical drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no eye drops)
Number of subjects: 0
Study: 3370077

Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30893430

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 50 U
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 29991757

Group type: EXPERIMENTAL
Intervention: Cellomics approach combining optogenetics and Brainbow technologies for high-throughput behavioral analysis.
Number of subjects: 0
Study: 27765756

Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg + gemcitabine/cisplatin (arm A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nivolumab + pemetrexed/cisplatin (arm B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nivolumab + paclitaxel/carboplatin/bevacizumab (arm C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nivolumab + docetaxel (arm D)
Number of subjects: 24
Study: 25903058

Group type: EXPERIMENTAL
Intervention: Prompt group (INT) received three daily screen-based prompts for 12 weeks.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-prompt group (CON) received only one instruction about the benefits of HAWDs.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Prompt group (INT) for concentration and neuromuscular performance.
Number of subjects: 38
Study: 23063263

Group type: EXPERIMENTAL
Intervention: Liver-directed therapy (including hepatic resection, thermal ablation, intra-arterial therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin analogues, sunitinib, and everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT)
Number of subjects: 0
Study: 20962287

Group type: EXPERIMENTAL
Intervention: Hallucinations with insight
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hallucinations without insight
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sleep fragmentation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Vivid dreams/nightmares
Number of subjects: 89

Group type: COMPARATOR
Intervention: Acting out dreams
Number of subjects: 89
Study: 18226435

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin with dexamethasone or chemotherapy
Number of subjects: 0
Study: 15691342

Group type: EXPERIMENTAL
Intervention: Gingivectomy (GV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open-flap debridement (OFD)
Number of subjects: 15
Study: 12534402

Group type: EXPERIMENTAL
Intervention: onercept 11.7 mg three times weekly for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: onercept 50 mg three times weekly for 2 weeks
Number of subjects: 12
Study: 11208371

Group type: EXPERIMENTAL
Intervention: Ligation of the main trunk of the inferior thyroid artery (Group 1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ligation of only the branches of the inferior thyroid artery (Group 2)
Number of subjects: 37
Study: 9275422

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg twice with 12 hours apart (Group 1)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Single dose of mifepristone 25 mg (Group 2)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg and anordrin 7.5 mg given once (Group 3)
Number of subjects: 300
Study: 1903336

Group type: EXPERIMENTAL
Intervention: Flecainide acetate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study: 6675183

Group type: EXPERIMENTAL
Intervention: End-to-side jejunoileal bypass (ES)
Number of subjects: 21

Group type: COMPARATOR
Intervention: End-to-end jejunoileal bypass (EE)
Number of subjects: 21
Study: 30589533

Group type: EXPERIMENTAL
Intervention: 125 mg of MDMA
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 30241302

Group type: EXPERIMENTAL
Intervention: CGA-added beverage daily for 16 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CGA-added beverage
Number of subjects: 38
Study: 26621909

Group type: EXPERIMENTAL
Intervention: Persistently elevated C-reactive protein (CRP) level (≥ 5 mg/L at both baseline and 24 weeks after ART initiation)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Persistently low CRP level
Number of subjects: 205
Study: 24445737

Group type: EXPERIMENTAL
Intervention: UVA irradiation of the skin with two standard erythemal doses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: UVA irradiation of the forearm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Acute dietary intervention aimed at modulating systemic nitrate availability
Number of subjects: 24
Study: 22236919

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19410576

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 21
Study: 17995496

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily for 48 weeks)
Number of subjects: 572

Group type: COMPARATOR
Intervention: E2/NETA (1 mg 17beta estradiol plus 0.5 mg norethisterone acetate daily for 48 weeks)
Number of subjects: 572
Study: 15522363

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 454

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 454
Study: 11498060

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical therapy (low ejection fraction subgroup)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (low ejection fraction subgroup)
Number of subjects: 0
Study: 9467540

Group type: EXPERIMENTAL
Intervention: 3.3 micrograms/kg.day recombinant human GH (rhGH)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg.day recombinant human GH (rhGH)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study: 7890448

Group type: EXPERIMENTAL
Intervention: Higher frequency response options presented prior to lower frequency response options
Number of subjects: 350

Group type: COMPARATOR
Intervention: Quantitativeness of response options and location of items within the questionnaire
Number of subjects: 350